MX9306006A - Combinaciones antagonistas ibuprofeno-h2. - Google Patents

Combinaciones antagonistas ibuprofeno-h2.

Info

Publication number
MX9306006A
MX9306006A MX9306006A MX9306006A MX9306006A MX 9306006 A MX9306006 A MX 9306006A MX 9306006 A MX9306006 A MX 9306006A MX 9306006 A MX9306006 A MX 9306006A MX 9306006 A MX9306006 A MX 9306006A
Authority
MX
Mexico
Prior art keywords
ibuprofen
heartburn
lysine
relief
salt
Prior art date
Application number
MX9306006A
Other languages
English (en)
Spanish (es)
Inventor
Thomas N Gates
William Slivka
Robert Mcmahon
Robert T Sims
Original Assignee
Merck & Co Inc
Mcneil Ppc Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc, Mcneil Ppc Inc filed Critical Merck & Co Inc
Publication of MX9306006A publication Critical patent/MX9306006A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MX9306006A 1992-09-29 1993-09-28 Combinaciones antagonistas ibuprofeno-h2. MX9306006A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US95344092A 1992-09-29 1992-09-29

Publications (1)

Publication Number Publication Date
MX9306006A true MX9306006A (es) 1995-01-31

Family

ID=25493996

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9306006A MX9306006A (es) 1992-09-29 1993-09-28 Combinaciones antagonistas ibuprofeno-h2.

Country Status (6)

Country Link
EP (1) EP0663839A4 (de)
JP (1) JPH08502254A (de)
AU (1) AU4931693A (de)
CA (1) CA2144155A1 (de)
MX (1) MX9306006A (de)
WO (1) WO1994007541A1 (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2349575A1 (en) 1998-11-17 2000-05-25 Nitromed, Inc. Nitrosated and nitrosylated h2 receptor antagonist compounds, compositions and methods of use
SE0000774D0 (sv) 2000-03-08 2000-03-08 Astrazeneca Ab New formulation
JP4756823B2 (ja) 2001-06-01 2011-08-24 ポーゼン インコーポレイテッド Ｎｓａｉｄを協調的に送達するための薬剤組成物
US8206741B2 (en) 2001-06-01 2012-06-26 Pozen Inc. Pharmaceutical compositions for the coordinated delivery of NSAIDs
SE0102993D0 (sv) 2001-09-07 2001-09-07 Astrazeneca Ab New self emulsifying drug delivery system
EP1919288A4 (de) * 2005-07-18 2009-12-16 Horizon Therapeutics Inc Famotidin- und ibuprofenhaltige arzneimittel und ihre verabreichung
US20080020040A1 (en) * 2006-07-18 2008-01-24 Horizon Therapeutics, Inc. Unit dose form for administration of ibuprofen
US8067451B2 (en) 2006-07-18 2011-11-29 Horizon Pharma Usa, Inc. Methods and medicaments for administration of ibuprofen
US8067033B2 (en) 2007-11-30 2011-11-29 Horizon Pharma Usa, Inc. Stable compositions of famotidine and ibuprofen
ATE539747T1 (de) * 2006-07-18 2012-01-15 Horizon Therapeutics Inc Verfahren und medikamente zur verabreichung von ibuprofen
NZ587202A (en) 2008-01-04 2013-03-28 Schabar Res Associates Llc Methods for measuring a patient response upon administration of a drug and compositions thereof
AU2009290712A1 (en) 2008-09-09 2010-03-18 Astrazeneca Ab Method for delivering a pharmaceutical composition to patient in need thereof
CA2764963C (en) 2009-06-25 2016-11-01 Astrazeneca Ab Method for treating a patient at risk for developing an nsaid-associated ulcer
CA2860231A1 (en) 2011-12-28 2013-07-04 Pozen Inc. Improved compositions and methods for delivery of omeprazole plus acetylsalicylic acid
WO2015163832A1 (en) * 2014-04-25 2015-10-29 Pharmacti̇ve İlaç Sanayi̇ Ve Ti̇caret A.Ş. An ibuprofen and famotidine combined composition having improved stability
US11324727B2 (en) 2020-07-15 2022-05-10 Schabar Research Associates, Llc Unit oral dose compositions composed of naproxen sodium and famotidine for the treatment of acute pain and the reduction of the severity of heartburn and/or the risk of heartburn
WO2022015784A1 (en) 2020-07-15 2022-01-20 Schabar Research Associates Llc Unit oral dose compositions composed of ibuprofen and famotidine for the treatment of acute pain and the reduction of the severity and/or risk of heartburn

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CY1398A (en) * 1981-09-04 1987-12-18 Glaxo Group Ltd Pharmaceutical compositions containing non-steroidal anti-inflammatory agents
NZ235877A (en) * 1989-11-02 1992-09-25 Mcneil Ppc Inc Composition comprising acetaminophen or nsaid and an h 1 or h 2 receptor blocker and/or proton pump inhibitor for treating overindulgence
US4994604A (en) * 1990-01-10 1991-02-19 Merck & Co., Inc. Formation and resolution of ibuprofen lysinate
US5009895A (en) * 1990-02-02 1991-04-23 Merck & Co., Inc. Sustained release with high and low viscosity HPMC

Also Published As

Publication number Publication date
EP0663839A1 (de) 1995-07-26
JPH08502254A (ja) 1996-03-12
AU4931693A (en) 1994-04-26
WO1994007541A1 (en) 1994-04-14
EP0663839A4 (de) 1998-06-03
CA2144155A1 (en) 1994-04-14

Similar Documents

Publication Publication Date Title
MX9306006A (es) Combinaciones antagonistas ibuprofeno-h2.
Ferrer-Brechner et al. Combination therapy with ibuprofen and methadone for chronic cancer pain
US4704405A (en) Rapid acting combination of sodium sulindac and a base
ES2057439T3 (es) Uso de una composicion para la fabricacion de un medicamento para tratar los sintomas de excesos o abusos de comida y bebida.
EP0320551A1 (de) NSAID-Zusammensetzungen mit einer gegen gastro-intestinale Beschädigung schützenden Mischung von gewissen H1- und H2-Rezeptorblockern
AR003121A1 (es) Antagonistas del receptor de adhesión, procedimiento para prepararlos, composiciones farmacéuticas que los contienen y su empleo para preparar medicamentos y combatir enfermedades
JPS61197517A (ja) 薬剤組成物
JPH04230330A (ja) 非ステロイド系抗炎症薬によつて起こる胃腸症候の緩和のための薬剤配合物と緩和法
MX9304564A (es) Combinaciones de relajante muscular-ibuprofen.
FR2385398A1 (fr) Compositions anti-inflammatoires contenant un compose du type phosphonate et un compose du type salicylate
AU656140B2 (en) Pharmaceutical compositions and methods for alleviating gastrointestinal distress symptoms induced by nonsteroidal anti-inflammatory drugs
MX9304563A (es) Combinaciones de dexibuprofen/antiacido/simeticona
Mehlisch Review of the comparative analgesic efficacy of salicylates, acetaminophen, and pyrazolones
DE3366910D1 (en) Pharmaceutical compositions and preparation thereof
Drug-Induced Prevention of nonsteroidal anti-inflammatory drug-induced gastroduodenal ulcers: role of mucosal protective and gastric antisecretory drugs
Mardirossian et al. Comparison of the analgesic efficacy of flurbiprofen and aspirin for postsurgical dental pain
JPH0314812B2 (de)
Stalnikowicz et al. Cimetidine decreases indomethacin induced duodenal mucosal damage in patients with acute musculoskeletal disorders.
EP0017169B1 (de) Entzündungshemmende Mischungen mit reduzierter ulcerogener Wirkung
US20060141027A1 (en) Sublingual administration of non-steroidal anti-inflammatory pharmacological substances
WHEATLEY Analgesic properties of fluproquazone
Rodrigo et al. Sucralfate and cimetidine as maintenance treatment in the prevention of duodenal ulcer recurrence
IL70407A (en) Synergistic analgesic pharmaceutical compositions in unit dosage form,comprising an analgesic agent and hydroxyzine
AU605538B2 (en) Pharmaceutical unit
Kajanoja Indomethacin in the treatment of primary dysmenorrhoea